Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Cardiff Oncology, Inc. reported revenue of $1M, down 13.2% year over year. Operating margin was -8256.3% and net margin -7732.0%, on a free-cash-flow margin of -6402.5% with capital expenditure at 7.4% of revenue. Every figure is computed directly from CRDF's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1M | -8256.3% | -7732.0% |
| FY2024 | $1M | -7123.1% | -6651.7% |
| FY2023 | $0M | -9305.7% | -8492.0% |
| FY2022 | $0M | -10337.3% | -10026.9% |
| FY2021 | $0M | -8037.6% | -7880.5% |
How does CRDF compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.